'Right-To-Try' Has US FDA Support: Scaled-Back House Bill Retains Agency Oversight

Commissioner Gottlieb’s recent remarks on pending federal 'Right-to-Try' legislation were his most positive to date; he pushed back on earlier versions that would have removed FDA from process. 

Washington DC Capitol dome detail with waving american flag

US FDA Commissioner Scott Gottlieb is signaling his general support for House legislation that would establish a federal “Right-to-Try” law, given that the bill would maintain FDA oversight of the expanded access process, including the requirement that patients receiving an investigational drug be protected under an IND.

“We are in favor of constructs that allow patients who have a terminal disease, who don't have access to any...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Pink Sheet

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By 

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By 

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.